No abstract

Here, we introduce the preparation of the hybrid nanocomposite-modified electrode consisting of reduced graphene oxide (RGO) and gold nanoparticles (AuNPs) using the one-step electrochemical method, allowing for the simultaneous and individual detection of dopamine (DA), ascorbic acid (AA), and uric acid (UA). RGO/AuNPs nanocomposite was formed on a glassy carbon electrode by the co-reduction of GO and Au3+ using the potentiodynamic method. The RGO/AuNPs nanocomposite-modified electrode was produced by subjecting a mixed solution of GO and Au3+ to cyclic sweeping from −1.5 V to 0.8 V (vs. Ag/AgCl) at a scan rate 10 mV/s for 3 cycles. The modified electrode was characterized by scanning electron microscopy, Raman spectroscopy, contact angle measurement, electrochemical impedance spectroscopy, and cyclic voltammetry. Voltammetry results confirm that the RGO/AuNPs nanocomposite-modified electrode has high catalytic activity and good resolution for the detection of DA, AA, and UA. The RGO/AuNPs nanocomposite-modified electrode exhibits stable amperometric responses for DA, AA, and UA, respectively, and its detection limits were estimated to be 0.14, 9.5, and 25 μM. The modified electrode shows high selectivity towards the determination of DA, AA, or UA in the presence of potentially active bioelements. In addition, the resulting sensor exhibits many advantages such as fast amperometric response, excellent operational stability, and appropriate practicality.

With their similar layered structures and complementary physicochemical properties, molybdenum disulfide (MoS2) and graphene nanosheets can be formed into MoS2/graphene heterostructures with improved electrical, optical, catalytic, and electrochemical properties, enabling promising applications. Here, we present a method to prepare MoS2/graphene nanocomposites by liquid-phase exfoliation through the combined processes of high shear mixing and ultrasonication in deionized water without additional additives, under ambient conditions. MoS2/graphene nanocomposites in large quantities can be achieved with a high-speed mixer homogenizer and a tip sonicator by optimizing the processing parameters for shear exfoliation, such as shearing speed, shearing time, ultrasonication time, and the weight ratio of bulk MoS2 to graphite. Optimum conditions are achieved by comparing the graphene concentration produced, I D/I G, I 2D/I G, and E2g–A1g values from the Raman spectra. This is an easily available and facile method, thereby rendering it an efficient route for large-scale industrial production. We also demonstrate the application of the MoS2/graphene nanocomposites to highly sensitive electrochemical sensors. When used to modify an electrode for electrochemical sensing, the MoS2/graphene nanocomposites exhibit excellent electrochemical performances in the detection of morin.

No abstract

This paper describes a simple strategy for the ultratrace level detection of Pb2+ ion based on G-quadruplex DNA and an electrochemically reduced graphene oxide (ERGO) electrode. First, ERGO was formed on a glassy carbon electrode (GCE) by the reduction of graphene oxide (GO) using cyclic voltammetry. Subsequently, a methylene blue (MB)-tagged, guanine-rich DNA aptamer (Apt) was attached to the surface of ERGO via π-π interaction, leading to the Apt-modified ERGO electrode. The presence of Pb2+ could generate the folding of Apt to a G-quadruplex structure. The formation of G-quadruplex resulted in detaching the Apt from the ERGO/GCE, leading to a change in redox current of the MB tag. Electrochemical measurements showed the proposed sensor had an exceptional sensitivity for Pb2+ with a linear range from 10−15 to 10−9 M and a detection limit of 0.51 fM. The sensor also exhibited high selectivity for Pb2+, as well as many other advantages, such as stability, reproducibility, regeneration, as well as simple fabrication and operation processes.

No abstract

The mass production of graphene is of great interest for commercialization and industrial applications. Here, we demonstrate that high-quality graphene nanosheets can be produced in large quantities by liquid-phase shear exfoliation under ambient conditions in organic solvents, such as 1-methyl-2-pyrrolidinone (NMP), with the assistance of urea as a stabilizer. We can achieve low-defect graphene (LDG) using this approach, which is relatively simple and easily available, thereby rendering it to be an efficient route for the mass production of graphene. We also demonstrate the electrochemical sensing of an LDG-modified electrode for the determination of doxorubicin (DOX). The sensor shows an enhanced electrocatalytic property towards DOX, leading to a high sensitivity (7.23 × 10−1 μM/μA) with a detection limit of 39.3 nM (S/N = 3).

Anticancer drugs, such as fluorouracil (5-FU), oxaliplatin, and doxorubicin (Dox) are commonly used to treat colorectal cancer (CRC); however, owing to their low response rate and adverse effects, the development of efficient drug delivery systems (DDSs) is required. The cellular prion protein PrPC, which is a cell surface glycoprotein, has been demonstrated to be overexpressed in CRC, however, there has been no research on the development of PrPC-targeting DDSs for targeted drug delivery to CRC. In this study, PrPC aptamer (Apt)-conjugated gold nanoparticles (AuNPs) were synthesized for targeted delivery of Dox to CRC. Thiol-terminated PrPC-Apt was conjugated to AuNPs, followed by hybridization of its complementary DNA for drug loading. Finally, Dox was loaded onto the AuNPs to synthesize PrPC-Apt-functionalized doxorubicin-oligomer-AuNPs (PrPC-Apt DOA). The PrPC-Apt DOA were spherical nanoparticles with an average diameter of 20 nm. Treatment of CRC cells with PrPC-Apt DOA induced reactive oxygen species generation by decreasing catalase and superoxide dismutase activities. In addition, treatment with PrPC-Apt DOA inhibited mitochondrial functions by decreasing the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, complex 4 activity, and oxygen consumption rates. Compared to free Dox, PrPC-Apt DOA decreased proliferation and increased apoptosis of CRC cells to a greater degree. In this study, we demonstrated that PrPC-Apt DOA targeting could effectively deliver Dox to CRC cells. PrPC-Apt DOA can be used as a treatment for CRC, and have the potential to replace existing anticancer drugs, such as 5-FU, oxaliplatin, and Dox.